Kornimate/medical-research-clean huggingface dataset:
oxygen in migraine treatment

Conditions: Migraine Headache; Oxygen

Summary: iin this study, the investigators planned to investigate effectiveness of supplemental oxygen in patients (18-65 years) who were diagnosed as headache related to migraine without aura in the emergency department (ed). patients who will be ordered standard migraine therapy (50 mg dexketoprofen and 10 mg metoclopramide hcl in 100 cc normal saline iv) by the physician blind to research, will be evaluated by the researchers before the treatment and patients met the study criteria will be included. included patients randomly divided to two group, study group will receive supplemental oxygen with face mask for 1 hour. patients' visual analog score (vas) will be measured at 0th, 15th, 30th and 60th minute of treatment. if there will not be a 50% decrease at vas score from the beginning, patients will be examined again by the physician again. patients who will be ordered 100 mg tramadol as rescue therapy by the physician, will be continued to observed, vas scores will be measured at 120th minute again. to avoid drug related bias, patients who will be ordered any other drug for primary care or rescue treatment other than mentioned above will not be included into the study.


Eligibility criteria:
inclusion criteria: with their medical history and ed evaluation being diagnosed as migraine related headache according to his 2018 classification, having vas \>40 at the beginning of the treatment, accepting to participate patient group who received standard migraine therapy (50 mg dexketoprofen and 10 mg metoclopramide hcl in 100 cc normal saline iiv). patient who received 100 mg tramadol as rescue therapy exclusion criteria: taking any analgesic in 6 hours before admission, patients who were diagnosed with all other types of primary headaches (migraine with aura, migraine status, tth, trigeminal autonomic cephalgia etc), patients using anticoagulants or have bleeding diathesis, pregnant and breastfeeding patients, patients had fever, patients diagnosed as secondary headaches, patients had focal neurologic findings, patients had heart, liver, or kidney failure, patients had peptic ulcer, patients had chronic obstructive pulmonary disease, patients had acute coronary syndrome, patients who were not stable hemodynamically patients who had history of acute dystonia or akathisia due to metoclopramide. -
evaluation of functional, neuroplastic and biomechanical changes induced by an intensive, playful early-morning treatment including lower limbs (early-habit-ile) in preschool children with uni and bilateral cerebral palsy

Conditions: Cerebral Palsy

Summary: an urgent priority in the field of paediatric neurorehabilitation is the development of effective early motor interventions. hand and arm bimanual intensive therapy including lower extremities (= habit-ile) applies the concepts of motor skill learning and intensive training to both the upper extremities (ue) and lower extremities (le) and has been shown to improve aspects of motor function of the ue and le in school age children with unilateral and bilateral cerebral palsy (cp) across the 3 levels of the international classification of functioning, disability and health (icfdh). the principles and content of habit-ile can be applied to pre-school children and this method is highly promising for early rehabilitation.

the primary objective of this study is to evaluate the effect of two weeks of early habit-ile on gross motor function in pre-school children with unilateral and and bilateral cerebral paralysy (cp), in comparison with two weeks of usual motor activity including usual rehabilitation (control group).

Eligibility criteria:
inclusion criteria: * child with unilateral cerebral palsy or child with bilateral cerebral palsy proven spastic or dyskinetic * aged from 1 to 4 years old (12 to 59 months) (age corrected if prematurity) able to follow instructions and to be able to carry out all the evaluations, according to his age exclusion criteria: * age\> 2 years old (35 months) or 4 years old (59 months) during the internship evaluation period * uncontrolled epilepsy * history of botulinum toxin injection or surgery in the 6 months preceding the study period or scheduled within 3 months (during the study period) * visual or cognitive impairment that may interfere with the management * common contraindications to magnetic resonance imaging (mri) such as metal implants

Keywords: cerebral palsy (cp) pre-school children with unilateral and bilateral cp
epiphrenic iii pilot trial

Conditions: Heart Failure

Summary: the epiphrenic iii pilot trial investigates whether a diaphragmatic stimulation by interventionally placed electrodes may improve heart function, symptoms and functional capacity in patients with severe heart failure.


Eligibility criteria:
inclusion criteria: * symptomatic heart failure (nyha functional classes ii, iii or iv) * reduced left ventricular ejection fraction (lvef) \<35% * guideline-recommended drug therapy exclusion criteria: * patient refuses study participation * life expectancy presumably \<1 year * pregnancy
dose-optimization study evaluating the efficacy, safety and tolerability of vyvanse (lisdexamfetamine dimesylate) in children aged 6-12 diagnosed with adhd

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Summary: assess the efficacy \& tolerability of vyvanse when children aged 6-12 years diagnosed with adhd are dosed to optimal effect.

dose-optimization study evaluating the efficacy, safety and tolerability of vyvanse (lisdexamfetamine dimesylate) in children aged 6-12 diagnosed with adhd

Eligibility criteria:
inclusion criteria 1. subject is a male or female aged 6-12 years inclusive at the time of consent. 2. females of child-bearing potential (focp) must have a negative serum beta human chorionic gonadotropin (hcg) pregnancy test at screening and a negative urine pregnancy test at baseline and agree to comply with any applicable contraceptive requirements of the protocol. 3. primary diagnosis of adhd based on a detailed psychiatric evaluation. 4. subjects must have a baseline adhd-rs-iv total score ≥28. 5. subject is functioning at an age-appropriate level intellectually. 6. comply with all the testing and requirements. 7. subject is able to swallow a capsule. 8. subject has blood pressure measurements within the 95th percentile for age, gender, and height. exclusion criteria 1. subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as post traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder or other symptomatic manifestations. 2. subject has conduct disorder. 3. subject has a documented allergy, hypersensitivity, or intolerance to amphetamines. 4. subject has failed to respond to one or more adequate courses (dose and duration) of amphetamine therapy. 5. the subject has a recent history (within the past 6 months) of suspected substance abuse or dependence. 6. subject has a positive urine drug result. 7. subject weighs less than 50 pounds (22.7kg). 8. subject is significantly overweight. 9. subject has a history of seizures (exclusive of febrile seizures), a tic disorder, a current diagnosis and/or family history of tourette's disorder. 10. subject has any reported history of abnormal thyroid function. 11. subject has taken another investigational product or taken part in a clinical trial within 30 days prior to screening. 12. subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments. 13. the female subject is pregnant or lactating. 14. subject is well-controlled on their current adhd medication with acceptable tolerability.
taking open label placebo further: trial of imaginary pills in test anxiety

Conditions: Test Anxiety

Summary: employing imaginary pills could offer a new way of investigating underlying mechanisms of open label placebo (olp) treatment by eliminating the physical treatment constituent (i.e., the pill itself). this can reveal the power of the purely psychological component of a placebo and gives insights into underlying mechanisms of placebo effects. the aim of the project is to assess possible effects of an imaginary pill in comparison to no treatment, and open label placebo treatment in subjects with test anxiety. interventions (seven to three weeks before the exam) will be held online using a video chat application such as zoom (https://zoom.us/) or skype (https://www.skype.com/de/) or will take place at the division of clinical psychology and psychotherapy, university of basel (missionsstrasse 62, 4055 basel).


Eligibility criteria:
inclusion criteria: * having an exam at the end of the semester, that is still at least four weeks ahead * self-reported fear of the exam (i.e., not clinical) * healthy by self-report statement (i.e., no known current or chronic somatic diseases or psychiatric disorders) * willing to participate in study exclusion criteria: * any acute or chronic disease (chronic pain, hypertension, heart disease, renal disease, liver disease, diabetes) * current medications (psychoactive medication, narcotics, intake of analgesics) * any psychiatric disorders or being currently in psychological or psychiatric treatment * insufficient german language skills to understand the instructions * daily consumption of more than three alcoholic standard beverages (a standard alcoholic beverage is defined as either 3dl beer or 1 dl wine or 2cl spirits) * current or regular drug consumption * being a master student in psychology * allergy of one of the ingredients of the placebo pills (p-dragees blue lichtenstein) * problems to swallow pills

Keywords: imaginary pills open label placebo (olp) treatment placebo
evaluation of a 6-month intragastric balloon

Conditions: Obesity and Overweight

Summary: post-market observational, adaptive, single-arm clinical study to evaluate the percentage of total weight loss after treatment with an intragastric balloon. patients will be followed for 6 months after the device is installed.

forty-six overweight patients over 18 years of age with a bmi of 27 kg/m2 or greater who are considered suitable for intragastric balloon placement will be included. the primary outcome will be the assessment of the percentage of total weight loss (%wl) at 6 months. patients will be screened in an outpatient setting at the participating research center. all participants who meet the eligibility criteria will be invited to participate in the study, which includes a screening visit, standard intragastric balloon placement procedure, and follow-up visits.

Eligibility criteria:
inclusion criteria: * signed informed consent form; * age 18 or older; * both sexes; * being overweight, with a body mass index (bmi) of 27 kg/m2 or higher; * being able to follow the protocol monitoring requirements; * adhering to the diet recommended by the nutrition professional; * presenting reasonable expectations of weight loss, at least 10% of baseline weight. exclusion criteria: * pregnant women or women during the breastfeeding period; * people unable or unwilling to comply with restrictions regarding diet or medical monitoring and their respective guidelines during the program for use of the intragastric balloon; * people with severe kidney and/or liver diseases; * patients who have undergone previous gastric surgery; * patients with inflammatory diseases of the gastrointestinal tract, gastric ulcer, duodenal ulcer or specific inflammations, such as crohn\&amp;#39;s disease, or with a propensity for gastrointestinal bleeding in the upper tract, such as esophageal or gastric varices, or acquired intestinal telangiectasia; * people with severe cardiopulmonary or organic disorders; * people with congenital or acquired anomalies of the gastrointestinal tract, such as atresia and stenosis; with large hiatal hernia; * drug addicts in general; * patients not committed to adhering to treatment and medical recommendations, including nutritional guidance.

Keywords: intragastric weight loss
endoangel withdrawal overspeed analysis

Conditions: Colorectal Neoplasms

Summary: exploring the relationship between the percentage of overspeed of colonoscopy withdrawal and the rate of adenoma detection.


Eligibility criteria:
inclusion criteria: 1. males or females who are over 18 years old (inclusive); 2. enteroscopy and related examinations are needed to further clarify the characteristics of digestive tract diseases; 3. able to read, understand and sign the informed consent form; 4. the researcher believes that the subject can understand the process of the clinical research, is willing and able to complete all the research procedures and follow-up visits, and cooperate with the research procedures. exclusion criteria: 1. participated in other clinical trials, signed an informed consent form and within the follow-up period of other clinical trials; 2. abuse of drugs or alcohol or mental disorders in the last 5 years; 3. women during pregnancy or breastfeeding; 4. subjects with previous history of bowel surgery; 5. the investigator believes that the subject is not suitable for enteroscopy and related examinations; 6. the investigator believes that the subject is not suitable for high-risk diseases or other special circumstances to participate in clinical trials. 7. patients with gastrointestinal bleeding; 8. known or highly suspected allergy to any ingredient of bowel cleansing agent; 9. restricted activities or any mental or physical condition impairs their ability to drink intestinal cleansing preparations; 10. known or suspected intestinal obstruction or perforation, toxic megacolon, most colectomy, heart failure (grade iii or iv), severe cardiovascular disease, severe liver failure or end, renal insufficiency, etc.
mridian "radar" trial

Conditions: Metastatic Epidural Spinal Cord Compression; Spinal Cord Compression

Summary: the main purpose of this study is to see if treating cancer with the magnetic resonance imaging guided adaptive radiotherapy (mridian) can control patient's tumor and eliminate the need for surgery used to treat nerves in the spine flattened by pressure (compressed).


Eligibility criteria:
inclusion criteria: 1. male and female participants ages ≥ 18. 2. solid tumors causing mescc for which surgery is an option as first-line treatment. 3. tumor histologies eligible for treatment include breast, prostate, sarcoma, melanoma, gastrointestinal types, nsclc and renal cancers. other solid malignancy types are also allowed at discretion of investigator if not specifically excluded by criteria. 4. mri of involved spine within 4 weeks prior to registration to determine extent of spine involvement. 5. bilsky scale ≥ 1c mescc with tumor ≤ 1 mm from the spinal cord or cauda equina nerve roots anywhere from c1 to terminus of cauda equina on screening mri. 6. protocol defined mescc must involve no more than 3 contiguous vertebral levels. mescc can involve multiple non-contiguous spinal canal regions within those 3 contiguous vertebral levels. 7. karnofsky performance score ≥60 8. survival prognosis ≥3 months 9. medical status allowing surgery. 10. neurologic exam within 1 week prior to registration and again within 1 week of first treatment to rule out severe neurologic deficits caused by disease at site of cord compression. 11. patients with mild to moderate cord neurologic signs are eligible if they are improved or stabilized by steroid. these neurologic signs include radiculopathy, dermatomal sensory change, and muscle strength of involved extremity 4/5 (lower extremity for ambulation or upper extremity for raising arms and/or arm function). 12. all patients must be ambulatory. 13. numerical rating pain scale within 1 week prior to registration (back pain permitted for enrollment) 14. spine instability neoplastic score \< 14 a. an exception to this criterion may be made if the patient is evaluated by a spinal surgeon and the surgeon defers surgery. 15. willing and able to undergo daily mri during treatment 16. willingness and able to use an acceptable method of contraception during the study and for at least 6 months after stopping the therapy. 17. eastern cooperative oncology group (ecog) performance status 0-2 18. history and physical within 2 weeks prior to registration 19. patients must provide study specific informed consent prior to study entry. exclusion criteria: 1. unknown primary histology 2. patients with rapid neurologic decline. 3. bony retropulsion causing neurologic abnormality 4. non-ambulatory patients. 5. prior radiation to the involved site. 6. inability to have an mri 7. pre-existing or concomitant neurological problems not related directly to mescc (e. g., neurologic deficits due to brain metastases) 8. very radiosensitive tumor histology (e.g., myeloma, seminoma, germ cell tumors, leukemia, and lymphoma) 9. patients with impaired decision-making capacity.
painful diabetic polyneuropathy trial with a new centrally acting analgesic

Conditions: Diabetic Polyneuropathy

Summary: the purpose of this trial is to determine whether the new centrally active analgesic and ms continus® are effective in the treatment of painful diabetic polyneuropathy.


Eligibility criteria:
inclusion criteria: * subjects with pain at least nrs \>4 due to painful diabetic polyneuropaty. exclusion criteria: * contraindications to, or history of allergy or hypersensitivity to morphine, fentanyl, hydrocodone, acetaminophen, heparin, polyethylene glycol 400 usp-nf or any compound planned to be used during the anesthesia, or their excipients. * non caucasian or hispanic. * concomitant painful disease. * life-long history of seizure disorder or epilepsy. * subjects with clinical relevant cardiac and vascular diseases. * subjects with impaired renal function * subjects with impaired hepatic function * female subjects who are pregnant or breastfeeding.

Keywords: analgesic diabetes mellitus chronic neuropathic pain painful polyneuropathy caused by diabetes mellitus type i or ii
haut-tief patient education on psoriasis and eczema

Conditions: Psoriasis; Atopic Dermatitis/ Eczema

Summary: 'haut-tief' (skin deep) is an educational, stress reducing program for patients with psoriasis or atopic dermatitis. a range of support activities will be offered in order to learn effective self-management strategies and attitude to one's chronic skin disease and consequently improving quality of life.

the educational program consists of 2-hours of educational (dermatology, specialized nurse, psychologist) and stress-reduction sessions (yoga, meditation, physiotherapy) twice a week during 9 weeks. a multidisciplinary team of trainers is involved. primary endpoint is the general and skin dependent quality of life measured by questionnaires. hrqol (health-related quality of life) is measured at baseline, after 3 months, 6 months and 9 months follow up. patients are recruited from the out-patient clinic at the department of dermatology of the university hospital zurich. patients are randomized in an intervention and control group. intervention group receives the education program additionally to follow-up visits whereas the control group receives follow-up visits. several runs are planned.

Eligibility criteria:
inclusion criteria: * chronic psoriasis (disease for more than 3 months) * chronic eczema (disease for more than 3) months) * age ≥ 18 years * oral and written informed consent exclusion criteria: * systemic antiinflammatory therapy * treatment with other investigational products * other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc), * known or suspected non-compliance, drug or alcohol abuse, * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia or confusional state of the subject * participation in another study within the 30 days preceding and during the present study, (viii) previous enrollment into the current study, * enrolment of the investigator, his/her family members, employees and other dependent persons.

Keywords: psoriasis atopic dermatitis eczema patient education stress reduction quality of life
acceptance and commitment therapy (act) in groups for obsessive compulsive disorder: a clinical trial in brazil

Conditions: Obsessive-Compulsive Disorder

Summary: the goal of this clinical trial is to learn if acceptance and commitment therapy (act) + exposure and response prevention (erp) in group is effective to obsessive compulsive disorder (ocd) in adults. researchers will compare intervention to control group to see if those who attend the group therapy have better results than control group. participants will go through a 16-week group therapy based on a protocol designed by michael twohig (twohig et al, 2018). * participants will not have any medication adjustment during therapy * participants will be assessed 3 times throughout the therapy, plus an assessment in a 6-month follow-up.

the goal of this clinical trial is to learn if acceptance and commitment therapy (act) + exposure and response prevention (erp) in group is effective to obsessive compulsive disorder (ocd) in adults. the main questions it aims to answer are: * can act in groups help decrease the severity of ocd symptoms? * can act in groups help increase psychological flexibility in this group? * can act in groups help increase quality of life in this group? researchers will compare intervention (n=16) to control group (n=8) to see if those who attend the group therapy have better results than control group. we will perform an unequal randomization in a 2:1 ratio, in blocks of 6, for allocation to each group. the assessor of the outcomes of interest will be blinded to the group to which the participant was assigned participants will go through a 16-week group therapy based on a protocol designed by michael twohig (twohig et al, 2018). * participants will not have any medication adjustment during therapy * participants will be assessed 3 times throughout the therapy, plus an assessment in a 6-month follow-up.

Eligibility criteria:
inclusion criteria: * ocd diagnosis according to dms-5/ minimum score of 20 in ybocs exclusion criteria: * psychotic disorder, maniac episode, intellectual disability, chemical dependency, suicidal risk, another current psychotherapy

Keywords: ocd obsessive-compulsive disorder